Teva Pharmaceutical Industries Ltd (TEVJF) Income from Continuing Operations (2009 - 2026)

Teva Pharmaceutical Industries (TEVJF) has 18 years of Income from Continuing Operations data on file, last reported at 576000000.0 in Q2 2026.

• Quarterly Income from Continuing Operations fell 304.98% year-over-year to 576000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 696000000.0 (up 516.77% YoY) and the FY2025 annual result came in at 1403000000.0, up 171.58% from the prior year.
• Income from Continuing Operations retreated to 576000000.0 in Q2 2026, from 370000000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 519000000.0 in Q1 2024 to a low of 1796000000.0 in Q4 2023.
• A 5-year average of 290500000.0 and a median of 264000000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1286.59% — and 2024, when it surged 305.14%.
• Tracing TEVJF's Income from Continuing Operations over 5 years: stood at 1334000000.0 in 2022, then sank by 34.63% to 1796000000.0 in 2023, then surged by 84.69% to 275000000.0 in 2024, then jumped by 270.91% to 470000000.0 in 2025, then tumbled by 222.55% to 576000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 576000000.0 (Q2 2026), 370000000.0 (Q1 2026), and 470000000.0 (Q4 2025), per Business Quant data.